Autolus Therapeutics (AUTL) Receivables - Net (2022 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Receivables - Net data on file, last reported at $24.0 million in Q4 2025.

• Quarterly Receivables - Net rose 160060.0% year-over-year to $24.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.0 million (up 160060.0% YoY) and the FY2025 annual result came in at $24.0 million, up 160060.0% from the prior year.
• Receivables - Net fell to $24.0 million in Q4 2025, from $32.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $32.6 million in Q3 2025 to a low of $15000.0 in Q4 2024.
• A 5-year average of $6.0 million and a median of $293000.0 in 2022 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net slumped 92.1% — and 2025, when it jumped 160060.0%.
• Tracing AUTL's Receivables - Net over 5 years: stood at $384000.0 in 2021, then sank by 68.49% to $121000.0 in 2022, then slipped by 9.92% to $109000.0 in 2023, then sank by 86.24% to $15000.0 in 2024, then jumped by 160060.0% to $24.0 million in 2025.
• The last three Receivables - Net figures came in at $24.0 million (Q4 2025), $32.6 million (Q3 2025), and $26.6 million (Q2 2025), per Business Quant data.